
UNAIDS DATA **2022** 148

FIJI

| EPIDEMIC ESTIMATES | | | |
|--|------------------|------------------|------------------|
| | 2010 | 2015 | 2021 |
| New HIV infections | | | |
| New HIV infections (all ages) | <100 | <200 | <200 |
| | [<100- <200] | [<100- <500] | [<100- <500] |
| New HIV infections (0–14) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <100] |
| New HIV infections (15-24) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <100] |
| New HIV infections (women, 15+) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <200] |
| New HIV infections (men, 15+) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <200] | [<100- <500] |
| HIV incidence (all ages) per 1000 population | 0.09 [0.06–0.15] | 0.12 [0.07–0.25] | 0.19 [0.09–0.44] |
| AIDS-related deaths | | | |
| AIDS-related deaths (all ages) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <100] |
| AIDS-related deaths (0–14) | <100 | <100 | <100 |
| | [<100-<100] | [<100- <100] | [<100- <100] |
| AIDS-related deaths (women, 15+) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <100] |
| AIDS-related deaths (men, 15+) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <100] |
| People living with HIV | | | |
| People living with HIV (all ages) | <500 | 790 | 1400 |
| | [<500–910] | [580–1400] | [900–2800] |
| People living with HIV (0-14) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <200] |
| People living with HIV (women, 15+) | <200 | <500 | 640 |
| | [<200-<500] | [<500–590] | [<500–1200] |
| People living with HIV (men, 15+) | <500 | <500 | 740 |
| | [<200- <500] | [<500–710] | [<500–1500] |
| HIV prevalence (15–49) | <0.1 [<0.1–0.2] | 0.1 [0.1–0.2] | 0.2 [0.2–0.5] |
| | | | |




^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 91% or higher (the testing and treatment target for 2025).

| EXPENDITURES | | | | | | | | | |
|-----------------------------|------------------|-----------------|--------------------------|-------------------------------|------------------------------|--------------|--|--|--|
| Financing sources | | | | | | | | | |
| | Domestic private | Domestic public | International: PEPFAR | International: Global Fund | International: all others | Total | | | |
| Last available report: 2016 | | US\$ 509 384 | | | US\$ 158 885 | US\$ 668 269 | | | |

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



| ELIMINATION OF VERTICAL TRANSMISSION | | | | | | |
|---|-----------------------|-----------------------|--|--|--|--|
| | 2015 | 2021 | | | | |
| Percentage of pregnant women living with HIV accessing antiretroviral medicines | 38% [27–69%] | 58% [40–100%] | | | | |
| Final vertical transmission rate including during breastfeeding | 24.4% [16.1–35.4%] | 21.1% [18.0–42.0%] | | | | |
| Early infant diagnosis | 35.1% [19.4–50.0%] | 69.8% [38.5- >95%] | | | | |